FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GARCÍA-TREVIJANO, E. R.
Right arrow Articles by AVILA, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GARCÍA-TREVIJANO, E. R.
Right arrow Articles by AVILA, M. A.
(The FASEB Journal. 2000;14:2511-2518.)
© 2000 FASEB

S-Adenosylmethionine regulates MAT1A and MAT2A gene expression in cultured rat hepatocytes: a new role for S-adenosylmethionine in the maintenance of the differentiated status of the liver

ELENA R. GARCÍA-TREVIJANO1, M. UJUE LATASA1, M. VICTORIA CARRETERO, CARMEN BERASAIN, JOSÉ M. MATO2 and MATÍAS A. AVILA

Unidad de Hepatología y Terapia Génica, Departamento de Medicina Interna, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain

2Correspondence: Departamento de Medicina Interna, Edificio Los Castaños, Facultad de Medicina, Universidad de Navarra, 31008, Pamplona, Spain. E-mail: jmmato{at}unav.es


   ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Methionine metabolism starts with the formation of S-adenosylmethionine (AdoMet), the most important biological methyl donor. This reaction is catalyzed by methionine adenosyltransferase (MAT). MAT is the product of two different genes: MAT1A, which is expressed only in the adult liver, and MAT2A, which is widely distributed, expressed in the fetal liver, and replaces MAT1A in hepatocarcinoma. In the liver, preservation of high expression of MAT1A and low expression of MAT2A is critical for the maintenance of a functional and differentiated organ. Here we describe that in cultured rat hepatocytes MAT1A expression progressively decreased, as described for other liver-specific genes, and MAT2A expression was induced. We find that this switch in gene expression was prevented by adding AdoMet to the culture medium. We also show that in cultured hepatocytes with decreased MAT1A expression AdoMet addition markedly increased MAT1A transcription in a dose-dependent fashion. This effect of AdoMet was mimicked by methionine, and blocked by 3-deazaadenosine and L-ethionine, but not D-ethionine, indicating that the effect was specific and mediated probably by a methylation reaction. These findings identify AdoMet as a key molecule that differentially regulates MAT1A and MAT2A expression and helps to maintain the differentiated status of the hepatocyte.—García-Trevijano, E. R., Ujue Latasa, M., Victoria Carretero, M., Berasain, C., Mato, J. M., and Avila, M. A. S-Adenosylmethionine regulates MAT1A and MAT2A gene expression in cultured rat hepatocytes: a new role for S-adenosylmethionine in the maintenance of the differentiated status of the liver.


Key Words: biological methylation • hepatocarcinoma • methionine metabolism • gene expression


   INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
S-ADENOSYLMETHIONINE (ADOMET) IS the most important methyl donor in cellular metabolism (1 , 2) . In mammals AdoMet can be synthesized in all cells of the organism, however, it is in the liver where most of the dietary methionine is converted into AdoMet and where up to 85% of all methylation reactions take place (3 , 4) . The first step in methionine metabolism is catalyzed by methionine adenosyltransferase (MAT) (2 3 4 5) . MAT is the product of two different genes, MAT1A and MAT2A, which code for two different enzymes, MATI/III and MATII respectively, with distinct kinetic and regulatory properties and that display a tissue-specific pattern of expression (2 , 5 6 7 8) . MAT1A is expressed only in the adult hepatocyte, whereas MAT2A shows a wider distribution and is responsible for AdoMet synthesis in extrahepatic tissues. In addition, MAT2A is expressed in the regenerating liver (9) and in the fetal hepatocyte, being replaced by MAT1A on maturation of the organ (10) . Interestingly, in hepatocarcinoma (rat and human-derived liver cancer cell lines and hepatocellular carcinoma specimens resected from patients) a similar situation can be found, and the dedifferentiated cell recovers the fetal pattern expressing MAT2A in place of MAT1A (11) . This switch in gene expression influences cellular AdoMet levels and appears to confer a growth advantage to the proliferating and transformed hepatic cell, probably through the differences in the MATI/III and MATII isozyme properties (12) .

In addition to the neoplastic liver, impaired AdoMet synthesis has been reported in chronic liver disorders such as alcoholic and viral cirrhosis, which in many cases precede the development of hepatocarcinoma, and in response to several hepatotoxins (including ethanol, carbon tetrachloride, galactosamine, and acetaminophen) (reviewed in ref 2 ). The pathological relevance of impaired AdoMet production can be inferred from the protective effects of exogenously administered AdoMet, as observed in experimental models of liver damage and in a recently reported clinical trial (2 , 13) . In addition, there is extensive evidence showing that liver carcinogenesis in rodents can be influenced by dietary restrictions in nutrients such as choline, methionine, folic acid, and vitamin B12, which compromise the cellular supply of methyl groups in the form of AdoMet (14) . The link between AdoMet availability and the preservation of a functional and differentiated liver is further supported by the chemopreventive effects of AdoMet administration on the development of preneoplastic lesions and hepatocellular carcinoma in models of rat liver carcinogenesis (15 , 16) .

All these evidences suggest that the preservation of an adequate methyl donor availability, and thus AdoMet levels, is central to the homeostasis of the liver, of which the pattern of MAT isozyme gene expression is a hallmark. In an experimental model of rat hepatocytes in primary culture, we have addressed the influence of cellular AdoMet contents on MAT1A and MAT2A expression. A new role for AdoMet in the maintenance of the differentiated status of the hepatocyte through the differential regulation of both genes is proposed.


   MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Materials
AdoMet, in the stable form of sulfate-p-toluenesulfonate salt produced by Knoll (Milan, Italy) was provided by Europharma (Madrid, Spain). All other reagents were of the best quality commercially available and otherwise stated they were purchased from Sigma (St. Louis, Mo.).

Isolation and culture of rat hepatocytes
Liver cells were isolated from male Wistar rats (200–250 g) by collagenase (Gibco-BRL, Paisley, U.K.) perfusion as described previously (17) . Cells were plated onto 60-mm collagen-coated culture dishes (type I collagen from rat tail; Collaborative Biomedical, Bedford, Mass.) at a density of 3 x 106 cells per dish. Cultures were maintained in MEM medium (Gibco-BRL) supplemented with 10% fetal calf serum (Gibco-BRL), nonessential amino acids (Gibco-BRL), 2 mM glutamine, 50 mM penicillin, and 50 mg/ml streptomycin sulfate (Gibco-BRL). After 2-h incubation the culture medium was removed and cultures were refed the same medium with 2.5% fetal calf serum. Cell viability was measured by trypan blue exclusion, and no significant differences were observed at any time between controls and any of the various treatments performed in this study.

Transient transfection of rat hepatocytes in culture
Hepatocytes were seeded as described above in collagen-coated multiwell dishes (5x105 cells per 30-mm well) 12 h before transfections. Cells were transfected with 5 µg of a MAT1A promoter-luciferase construct encompassing 1.4 kb of the 5'-flanking region of this gene (nucleotides -1405 to +65) (18) , using the TFx50 reagent (Promega) according to the manufacturer’s instructions. Five micrograms of the ß-galactosidase expression vector pCH110 (Amersham, Little Chalfont, U.K.) were included as an internal standard of transfection efficiency. After 24 h, cells were harvested and luciferase and galactosidase activities were determined as described (18) . Values reported are means of three independent experiments performed in duplicate.

Determination of AdoMet levels in cultured hepatocytes
After extensive washing with saline, cells were lysed and deproteinized with 0.4 M perchloric acid and centrifuged at 12000 g for 30 min at 4°C. Supernatants were analyzed by reverse-phase high-performance liquid chromatography as described previously (19) .

RNA isolation and Northern blot analysis
Total hepatocyte RNA was isolated by the guanidinium thiocyanate method (20) . Aliquots (15 µg) of total RNA were size-fractionated by electrophoresis in a 1% agarose gel under denaturing conditions. RNAs were then blotted and fixed to Nytran membranes (Schleicher & Schuell, Keene, N.H.). Prehybridization and hybridization were performed as described previously (21) . Rat cDNA probes for MAT1A, MAT2A, and albumin (22 23 24) were labeled with [{alpha}-32P]dCTP (Amersham) by random priming. Hybridization with a probe for 18S rRNA was performed as a loading control. Membranes were then exposed to X-ray films and signals were quantitated using the Molecular Analyst software (Bio-Rad, Hercules, Calif.).

Immunoblot analysis
For determination of MATI/III (the product of MAT1A gene) protein levels (6) , hepatocytes were homogenized as described previously (21) . Equal amounts of protein (20 µg) were subjected to 10% sodium dodecyl sulfate-polyacrilamide gel electrophoresis. Proteins were electrophoretically transferred to nitrocellulose membranes. Immunodetection of MATI/III was performed using a rabbit anti-rat MATI/III antiserum (25) and a horseradish peroxidase-conjugated secondary antibody. Blots were developed by enhanced chemoluminiscence according to manufacturer’s instructions (Dupont, Boston, Mass.). To demonstrate that the observed effects were specific and that equal loading of the gels had been achieved, after immunodetection of MATI/III membranes were stripped and reprobed with an antibody specific for actin (Calbiochem-Novabiochem, Darmstadt, Germany).

Statistics
Unless otherwise stated, the data are the means ± SE of at least four independent experiments. Statistical significance was estimated with Student’s t test. A P value of <0.05 was considered significant.


   RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Rat hepatocytes were placed in primary culture and the levels of MAT1A expression were determined by Northern blotting at the onset of cultures (t=0) and after 12 h of incubation. In agreement with other studies on the expression of liver-specific genes in cultured hepatocytes (26 27 28) , a sharp reduction in MAT1A mRNA was observed (Fig. 1A ). However, if AdoMet was added to cultured hepatocytes at t = 0 and MAT1A mRNA was evaluated 12 h later a clear dose-dependent protection in the reduction of this mRNA was observed (Fig. 1A ). AdoMet concentrations between 2 and 4 mM resulted in MAT1A mRNA levels similar to those found in recently isolated hepatocytes. This effect on MAT1A mRNA resulted in higher MATI/III protein levels, as determined by immunoblotting performed on cellular extracts from hepatocytes cultured for 18 h in the absence or presence of AdoMet (2 mM) (Fig. 1B ). The effect of AdoMet on MATI/III protein was specific, because the levels of other cellular proteins such as actin were not affected by this treatment (Fig. 1B ).



View larger version (14K):
[in this window]
[in a new window]
 
Figure 1. Effect of AdoMet on MAT1A expression in cultured rat hepatocytes. A) Rat hepatocytes were cultured as described in Materials and Methods. MAT1A mRNA levels were evaluated by Northern blotting at the onset of cultures (t=0) and after 12 h of incubation in the absence or presence of different concentrations of AdoMet. Blots were hybridized with an 18S rRNA cDNA probe to demonstrate equal loading. Representative blots are shown. B) MATI/III protein levels analyzed by Western blotting in rat hepatocytes cultured for 18 h in the absence or presence of 2 mM AdoMet (upper panel). Blots were also probed with an antibody for actin protein to demonstrate equal loading and the specificity of the effect of AdoMet (lower panel). Representative blots are shown.

We next wanted to know at which level the AdoMet was acting on MAT1A expression. Steady-state mRNA levels are controlled through the interplay of various mechanisms. These mechanisms generally include the regulation of gene transcription and messenger stability. In an initial approach we tested whether AdoMet was able to reinduce MAT1A expression after its decay in culture. For this purpose, isolated hepatocytes were cultured for 12 h, then AdoMet (4 mM) was added to cells and incubation continued for another 12 h. MAT1A mRNA levels were measured at the onset of cultures (t=0), after the initial 12 h of culture, and after an additional 12 h of AdoMet treatment. When compared with control cultures (in the absence of AdoMet), a sharp induction of MAT1A mRNA levels was observed in response to AdoMet addition (Fig. 2A ). The accumulation of newly synthesized MAT1A mRNA suggested that the transcription of this gene could be stimulated in response to AdoMet. Further support for this hypothesis was obtained by treating cells with AdoMet in the presence of the transcriptional inhibitor actinomycin D. Under these conditions, the effect of AdoMet was completely blocked (Fig. 2A ). Actinomycin D also prevented the effect of AdoMet on MAT1A expression when both agents were added to hepatocytes at the onset of cultures (t=0) (data not shown). Finally, direct evidence of AdoMet action on MAT1A gene promoter was obtained in transient transfection experiments using a construct encompassing the reporter gene luciferase under the control of rat MAT1A 5'-flanking region (18) . Luciferase activity in lysates from hepatocytes transiently transfected with this construct was induced in a dose-dependent fashion in response to AdoMet treatment (Fig. 2B ). In parallel experiments, treatment of hepatocytes with the glucocorticoid triamcinolone (1 µM) also resulted in the activation of MAT1A promoter and the induction of luciferase activity levels similar to those found with AdoMet treatment at 2 mM (data not shown). Taken together, these observations indicated that AdoMet was promoting MAT1A transcription.



View larger version (25K):
[in this window]
[in a new window]
 
Figure 2. Effect of AdoMet on MAT1A transcription in cultured rat hepatocytes. A) Hepatocytes were cultured for 12 h and then 4 mM AdoMet was added to culture media (arrow) in the presence or absence of actinomycin D (5 µg/ml) and incubations continued for another 12 h. MAT1A mRNA levels were determined by Northern blotting in the absence of AdoMet (•), in AdoMet-treated cells ({blacksquare}) and in AdoMet plus actinomycin D-treated cells ({Delta}). Data are means ± SE. B) Hepatocytes were transfected with a construct harboring 1.4 kb of MAT1A promoter coupled to a luciferase reporter gene as described in Materials and Methods. Luciferase activity was measured in cell lysates of control and AdoMet-treated hepatocytes after 24 h of incubation. Luciferase activities, normalized for ß-galactosidase expression, are expressed as fold increase with respect to untreated controls. *P<0.05 with respect to control values. Data are means ± SE

It is known that AdoMet levels are reduced with time in isolated and cultured rat hepatocytes (17) . We wanted to know whether in our culture conditions the exogenously added AdoMet could restore the intracellular pool of this compound. In agreement with previous studies on AdoMet uptake by liver or isolated hepatocytes (29 30 31) , we observed that intracellular AdoMet levels were threefold higher than control levels after 5 min of incubation in the presence of 2 mM and eightfold higher with 4 mM of exogenously added AdoMet (81±24 pmol/mg of protein in control vs. 275±75 for 2 mM AdoMet and 675±102 for 4 mM AdoMet). Incubation for 5 min with 2 mM L-methionine also increased hepatocyte AdoMet concentration ~2.4-fold.

We were also interested in the molecular mechanisms through which AdoMet could mediate its effects on MAT1A expression. In this respect, we observed that L-methionine, the precursor of AdoMet together with ATP, was able to partially mimic the AdoMet effect on MAT1A mRNA levels after 12 h of treatment at a concentration of 2 mM. However, under the same conditions, the nonmetabolizable D-isomer of methionine elicited no response (Fig. 3 ), suggesting that methionine had to be metabolized to AdoMet to stimulate MAT1A expression and that dietary methionine may thus modulate the expression of this gene. Additional insight into the mechanism of AdoMet action was obtained with two other experimental approaches. First, when AdoMet treatment was performed in the presence of 10 µM of the adenosine analog 3-deaza-adenosine (C3-Ado) (32) , the induction of MAT1A expression was substantially impaired (Fig. 3) . C3-Ado is an inhibitor of S-adenosylhomocysteine hydrolase and leads to a significant increase in the intracellular levels of S-adenosylhomocysteine (AdoHcy), additionally it can be converted into the more stable 3-deaza-derivative of AdoHcy (S-3-deaza-adenosylhomocysteine, C3-AdoHcy) (32) . AdoHcy and C3-AdoHcy are strong inhibitors of methylation reactions (2 , 32) . Second, under similar conditions the simultaneous addition of AdoMet and L-ethionine (2 mM), the ethyl analog of methionine, resulted in the impairment of AdoMet action (Fig. 3) . If instead of L-ethionine cells were treated with D-ethionine, AdoMet induction of MAT1A expression was not affected (data not shown). Ethionine is also a substrate for MATI/III, which converts it into S-adenosylethionine, a molecule that is only slowly metabolized further and thus accumulates in the cell and inhibits AdoMet actions (33 , 34) .



View larger version (27K):
[in this window]
[in a new window]
 
Figure 3. Mechanism of AdoMet regulation of MAT1A expression. Hepatocytes were treated with 2 and 4 mM AdoMet; 2 mM L-methionine; 2 mM D-methionine; 2 mM L-ethionine; 2 mM AdoMet plus 2 mM L-ethionine; 10 µM C3-Ado; 10 µM C3-Ado plus 4 mM AdoMet for 12 h and MAT1A mRNA levels were determined by Northern blotting. *Differences were statistically significant (P<0.05) with respect to control levels (control: without AdoMet). **Differences between 2 mM AdoMet vs. 2 mM AdoMet plus L-ethionine, and 4 mM AdoMet vs. 4 mM AdoMet plus C3-Ado were statistically significant (P<0.05). Data are means ± SE.

The overall transcriptional activity of cultured hepatocytes was not stimulated by AdoMet treatment in a nonspecific fashion. This was confirmed when AdoMet effects on another liver-specific gene such as albumin were tested. In this case, and as previously reported, albumin expression decayed with time in culture; however, AdoMet treatment was not able to prevent it, whereas under the same conditions the down-regulation of MAT1A mRNA was almost completely reversed (Fig. 4A , C ). As mentioned in the introduction the progressive decay in the expression of liver-specific genes such as MAT1A and albumin observed in cultured hepatocytes is often accompanied by the activation of other genes that are not normally expressed in this organ. Some of these genes, such as the uncoupling protein 2 (UCP2) and the enzyme telomerase, have been proposed to provide the hepatic cell with metabolic traits that favor a proliferative phenotype (28 , 35 , 36) . This is supported by the fact that such genes are also activated in transformed hepatic cells (28 , 36) . These observations led us to examine the expression of MAT2A in our model of cultured hepatocytes. Interestingly, MAT2A expression was already elevated 12 h after hepatocytes were plated (data not shown), and levels increased significantly after 24 h in culture (Fig. 4B ). More remarkably, when cells were cultured for 24 h in the presence of AdoMet (4 mM), the induction of MAT2A expression was completely prevented (Fig. 4B ).



View larger version (35K):
[in this window]
[in a new window]
 
Figure 4. MAT1A, albumin, and MAT2A mRNAs in cultured rat hepatocytes: effect of AdoMet treatment. A) MAT1A mRNA levels were reduced after 12 h in culture (t=12 h). This was prevented by AdoMet (AdoMet 12 h). B) MAT2A expression was induced with time in culture (t=24 h), this induction was prevented in the presence of AdoMet (AdoMet t=24 h). Blots were hybridized with a probe for 18S rRNA to check for equal loading. C) Albumin gene expression was examined in cultured hepatocytes in the absence or presence of AdoMet. *Differences were statistically significant (P<0.05) with respect to controls at t = 0. **Statistically significant differences (P<0.05) between AdoMet treated and untreated hepatocyte cultures. Representative blots are shown. Data are means ± SE.


   DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
As we mentioned, an adequate supply of one-carbon units to the liver is essential for the preservation of its differentiated functions. When the flow of one-carbon units is impaired, because severe dietary restrictions or liver damage, many of the tissue-specific functions of this organ are compromised and can be subsequently lost in a transition to a preneoplastic condition. An early biochemical event in these situations is the reduced availability of AdoMet, which may be because of a shortage of its precursor (as in methionine-choline-deficient diets) (14) , impaired synthesis because of the inactivation of MATI/III or impaired MAT1A expression, or the overall derangement of the methionine cycle (2 , 7 , 11) . The beneficial effects of AdoMet administration in such situations, which include the prevention of the neoplastic conversion of the liver, further support the importance of this metabolic pathway and a role for this compound in the maintenance of liver functions (2 , 13 , 15 , 16 , 29) . However, the molecular mechanisms of these effects of AdoMet are not fully understood.

The preservation of MAT1A expression, and thus MATI/III activity, is a fundamental trait of the healthy and differentiated hepatocyte. Loss of MAT1A expression accompanies the malignant transformation of the liver, and its replacement by the product of MAT2A gene appears to confer a growth advantage to the transformed cell (12) . In this context, we wanted to know whether cellular AdoMet levels could influence the expression of the methionine-metabolizing gene MAT1A. For this purpose, we turned to an experimental model of rat hepatocytes in primary culture in which this hypothesis could be directly addressed. It has been shown that cultured hepatocytes tend to lose the expression of liver-specific genes as a function of time in culture, reflecting a certain degree of de-differentiation (26 , 27) . In agreement with these notions, we observe a progressive reduction in MAT1A mRNA steady-state levels with culture time. When AdoMet was added to hepatocytes at the onset of cultures, the decrease in MAT1A mRNA levels was prevented in a dose-dependent manner. The effect of AdoMet was very potent and at certain concentrations MAT1A mRNA expression returned to levels found in recently isolated hepatocytes. This effect on MAT1A mRNA was also observed at the protein level and proved to be specific because the amount of other cellular proteins, such as actin, was not affected.

In our culture conditions, we have observed a dose-dependent increase in intracellular AdoMet on addition of this compound to the medium. Because of the low membrane permeability of AdoMet, high extracellular concentrations in the culture media had to be used to increase significantly the intracellular AdoMet content. The increase of intracellular AdoMet content observed under these conditions is likely to occur in vivo after feeding a methionine reach diet. It should be noted that cellular uptake of exogenous AdoMet is a controversial issue and that conflicting data can be found in the literature (30 , 31 , 37) . However, even in those studies, in which it was concluded that AdoMet was not found to be taken up by cells, when concentrations >200 µM were used, intracellular levels of AdoMet were increased (31) . Thus, it has been proposed that by increasing the extracellular concentrations of AdoMet above certain levels, the intracellular pool of this compound can be modulated (37) , and such was our purpose in the present experiments.

Gene expression regulation in mammalian cells can be achieved at various levels. The two main processes involved are the modulation of gene transcription and the control of mRNA stability. Under these premises, we next addressed the mechanisms that could mediate the effects of AdoMet on MAT1A mRNA levels. Our observations indicate that AdoMet effects on MAT1A mRNA levels took place mainly at the transcriptional level. Several lines of evidence support this notion. 1) AdoMet effects on MAT1A mRNA levels were suppressed in the presence of the transcriptional inhibitor actinomycin D when both agents were added together at the onset of cultures; 2) AdoMet was able to reinduce MAT1A expression after 12 h of decay in culture, reaching levels close to those found in recently isolated hepatocytes; 3) the reinduction of MAT1A expression was completely blocked by actinomycin D; and 4) AdoMet was able to dose-dependently stimulate reporter gene expression in transient transfection experiments in which the rat MAT1A promoter coupled to the luciferase gene was introduced in cultured hepatocytes. The magnitude of this effect, at 2 mM AdoMet, was similar to the response elicited by saturating concentrations of glucocorticoids, which we have previously described as potent regulators of MAT1A gene expression in liver parenchymal cells (38) . Although the identity of the promoter elements and binding factors responsible for AdoMet effect have not been identified yet, this observation strongly supports the activation of MAT1A gene transcription by AdoMet.

The precise mechanisms through which AdoMet stimulated MAT1A transcription are still not known; nevertheless, we have performed a series of experiments that suggest the likely involvement of a methylation reaction. We observed that AdoMet effect on MAT1A mRNA levels were blunted when cells were treated in the presence of the adenosine analog C3-Ado. This compound raises intracellular concentrations of AdoHcy and C3-AdoHcy, potent competitive inhibitors of transmethylation reactions (2 , 3 , 32) . Similarly, L-ethionine also interfered with the effects of AdoMet on MAT1A mRNA. L-Ethionine is adenylated at the expense of ATP to produce S-adenosylethionine, a compound that is only slowly metabolized further (33 , 34) . S-Adenosylethionine accumulates in the cell and competes with AdoMet in transmethylaton reactions (39) . The effect of L-ethionine was mediated through its conversion into S-adenosylethionine, because the nonmetabolizable isomer, D-ethionine, at the same concentration did not interfere with AdoMet induction of MAT1A expression (data not shown). Taken together, these observations suggest that a methyl transfer reaction participates in the mechanism of action of AdoMet. In addition, these data also support the idea that AdoMet would be acting intracellularly, where AdoHcy induced by C3-Ado, and S-adenosylethionine are synthesized and accumulated. AdoMet effects were partially mimicked by L-methionine treatment of cultured hepatocytes. This effect is probably mediated through the conversion of this amino acid to AdoMet, because D-methionine, which is not a substrate of MATI/III, did not affect MAT1A expression. In addition, these observations may contribute to explain the observed elevation in rat liver MATI/III activity in response to increased dietary methionine through the enhancement in MAT1A expression (40 , 41) .

As mentioned before, and as we observe in the case of MAT1A, hepatocytes isolated from healthy livers tend to lose the expression of liver-specific genes with time in culture (26 , 27) . Concomitantly, it has been realized that other genes that are not normally expressed in the differentiated liver, but that are activated in hepatocarcinoma cells, become induced (28 , 35 , 36) . Such genes are thought to endow the hepatic cell with metabolic traits compatible with a proliferate phenotype (28 , 35) . Thus, in this regard it has been proposed that the cultured hepatocyte reproduces to a certain extent some of the genetic changes that occur during the neoplastic conversion of the liver. Our present observation of MAT2A expression induction in cultured hepatic cells fits well within this hypothesis. Indeed, MAT2A expression is induced when normal hepatocytes proliferate after partial hepatectomy (9) and because of malignant transformation (11 , 12 , 42) . Nevertheless, what we find more interesting is the inhibition of MAT2A expression by AdoMet treatment. Thus, in response to this agent we observe the simultaneous, although opposed, regulation of MAT1A and MAT2A expression in the same cell, whereas the decay in albumin gene expression was not affected.

Although it is possible that AdoMet only prevents the change in MAT1A/MAT2A gene expression, without affecting the expression of other genes, these effects may be relevant to the preservation of the differentiated status of the hepatocyte regarding methionine metabolism. Our observations demonstrate the exquisite specificity of AdoMet effects on ‘hepatocyte gene expression. Additionally, these data strongly suggest that the maintenance of certain AdoMet levels can be crucial in preventing changes in gene expression that may contribute to the development of a preneoplastic phenotype. In addition, our results may contribute to an understanding of the mechanisms underlying the hepatocarcinogenic effects of experimental models in which liver AdoMet levels are persistently reduced, such as methionine-choline-deficient diets and the administration of agents such as ethionine and diethylnitrosamine (14 , 16 , 39 , 43) . These novel actions of AdoMet may also be behind the preventive effect of this compound in the development of chemically induced hepatocarcinoma, a model in which AdoMet administration results in growth inhibition and the remodeling of preneoplastic lesions (15 , 16) , and in the inhibition of cellular growth in AdoMet-treated human hepatocarcinoma cells in culture (12) .

In summary, our present results lead us to propose a novel role for AdoMet in the specific regulation of liver gene expression. These novel actions of AdoMet may open a new scenario in the biological roles played by this molecule, which now could be regarded also as an hepatotrophic agent involved in the preservation of the differentiated status of the hepatocyte, at least regarding one-carbon metabolism.


   ACKNOWLEDGMENTS
 
This work was supported by grants SAF 98/0132, SAF 99/0038 from CICYT (Spain), Europharma, and Knoll to J. M. M, grant 923/98 from Gobierno de Navarra to M. A. A. M., and grant AA12677-01A1 from the National Institutes of Health to M. A. A. and J. M. M. U. L. is a fellow of Fundación Renal Íñigo Álvarez de Toledo; E. R. G. T. and M. V. C. are fellows of the Universidad de Navarra. We thank Estefanía Fenández for technical help.


   FOOTNOTES
 
1 Both authors made equal contribution to this work.

Received for publication March 30, 2000. Revision received May 25, 2000.
   REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
 

  1. Cantoni, G. L. (1975) Biochemical methylations: selected aspects. Annu. Rev. Biochem. 44,435-441[Medline]
  2. Mato, J. M., Alvarez, L., Ortiz, P., Pajares, M. A. (1997) S-Adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol. Ther. 73,265-280[Medline]
  3. Finkelstein, J. D. (1990) Methionine metabolism in mammals. J. Nutr. Biochem. 1,228-236[Medline]
  4. Mudd, S. H., Poole, J. R. (1975) Labile methyl balances for normal humans on various dietary regimens. Metabolism 24,721-735[Medline]
  5. Kotb, M., Geller, A. M. (1993) Methionine adenosyltransferase: structure and function. Pharmacol. Ther. 59,125-143[Medline]
  6. Kotb, M., Mudd, S. H., Mato, J. M., Geller, A. M., Kredich, N. M., Chou, J. Y., Cantoni, G. L. (1997) Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products. Trends Genet. 13,51-52[Medline]
  7. Torres, L., Avila, M. A., Carretero, M. V., Latasa, M. U., Caballería, J., López-Rodas, G., Boukaba, A., Lu, S. C., Franco, L., Mato, J. M. (2000) Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during transformation. FASEB J 14,95-102[Abstract/Free Full Text]
  8. Torres, L., López-Rodas, G., Latasa, M. U., Carretero, M. V., Boukaba, A., Rodríguez, J. L., Franco, L., Mato, J. M., and Avila, M. A. (2000) DNA methylation and histone acetylation of rat methionine adenosyltransferase 1 A and 2 A genes is tissue-specific. Int. J. Biochem. Cell Biol. In press
  9. Huang, Z. Z., Mao, Z., Cai, J., Lu, S. C. (1998) Changes in methionine adenosyltrasnferase during liver regeneration in the rat. Am. J. Physiol. 275,G14-G21[Abstract/Free Full Text]
  10. Gil, B., Casado, M., Pajares, M. A., Boscá, L., Mato, J. M., Martín-Sanz, P., Alvarez, L. (1996) Differential expression pattern of S-adenosylmethionine synthetase isoenzymes during rat liver. Hepatology 24,876-881[Medline]
  11. Cai, J., Sun, W., Hwang, J., Stain, S. C., Lu, S. C. (1996) Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance. Hepatology 24,1090-1097[Medline]
  12. Cai, J., Mao, Z., Hwang, J., Lu, S. C. (1998) Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. Cancer Res 58,1444-1450[Abstract/Free Full Text]
  13. Mato, J. M., Cámara, J., Fernández de Paz, J., Caballería, L., Coll, S., Caballero, A., García-Buey, L., Beltrán, J., Benita, V., Caballería, J., Solà, R., Moreno-Otero, R., Barrao, F., Martín-Duce, A., Correa, J. A., Parés, A., Barrao, E., García-Magaz, I., Puerta, J. L., Moreno, J., Boissard, G., Ortiz, P., Rodés, J. (1999) S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J. Hepatol. 30,1081-1089[Medline]
  14. Newberne, P. M., Rogers, A. E. (1986) Labile methyl groups and the promotion of cancer. Annu. Rev. Nutr. 6,407-432[Medline]
  15. Garcea, R., Daino, L., Pascale, R., Simile, M. M., Puddu, M., Frassetto, S., Cozzolino, P., Seddaiu, M. A., Gaspa, L., Feo, F. (1989) Inhibition of promotion and persistent nodule growth by S-adenosyl-L-methionine in rat liver carcinogenesis: role of remodeling and apoptosis. Cancer Res 49,1850-1856[Abstract/Free Full Text]
  16. Pascale, R. M., Marras, V., Simile, M. M., Daino, L., Pinna, G., Bennati, S., Carta, M., Seddaiu, M. A., Massarelli, G., Feo, F. (1992) Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: a long-term study. Cancer Res 52,4979-4986[Abstract/Free Full Text]
  17. Avila, M. A., Carretero, M. V., Rodriguez, E. N., Mato, J. M. (1998) Regulation by hypoxia of methionine adenosyltransferase activity and gene expression in rat hepatocytes. Gastroenterology 114,364-371[Medline]
  18. Alvarez, L., Sánchez-Góngora, E., Mingorance, J., Pajares, M. A., Mato, J. M. (1997) Characterization of rat liver-specific methionine adenosyltransferase gene promoter. J. Biol. Chem. 272,22875-22883[Abstract/Free Full Text]
  19. Henning, S. M., McKeer, W., Swendseid, M. E. (1989) Hepatic content of S-adenosylmethionine and glutathione in rats receiving treatments modulating methyl donor availability. J. Nutr. 119,1478-1482
  20. Chomczynski, P., Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162,156-159[Medline]
  21. Avila, M. A., Velasco, J. A., Cho, C., Lupu, R., Wen, D., Notario, V. (1995) Hyperactive autocrine loop mediated by a NDF-related factor in neoplastic hamster embryo fibroblasts expressing an activated cph oncogene. Oncogene 10,963-971[Medline]
  22. Alvarez, L., Asunción, M., Corrales, F., Pajares, M. A., Mato, J. M. (1991) Analysis of the 5' noncoding region of the rat liver S-adenosylmethionine synthetase mRNA and comparison of the Mr deduced from the cDNA sequence and the purified enzyme. FEBS Lett 290,142-146[Medline]
  23. Horikawa, S., Sasuga, J., Shimizu, K., Ozasa, K., Tsukada, K. (1990) Molecular cloning and nucleotide sequence of cDNA encoding the rat kidney S-adenosylmethionine synthetase. J. Biol. Chem. 265,13683-13686[Abstract/Free Full Text]
  24. Sargent, T. D., Wu, J. R., Sala-Trepat, J. M., Wallace, R. B., Reyes, A. A., Bonner, J. (1979) The rat serum albumin gene: analysis of cloned sequences. Proc. Natl. Acad. Sci. U. S. A. 76,3256-3260[Abstract/Free Full Text]
  25. Ruiz, F., Corrales, F. J., Miqueo, C., Mato, J. M. (1998) Nitric oxide inactivates rat hepatic methionine adenosyltransferase in vivo by S-nitrosylation. Hepatology 28,1051-1057[Medline]
  26. Caron, J. M. (1990) Induction of albumin gene transcription in hepatocytes by extracellular matrix proteins. Mol. Cell. Biol. 10,1239-1243[Abstract/Free Full Text]
  27. Schuetz, E. G., Li, D., Omiecinski, C. J., Muller-Eberhard, U., Kleinman, H. K., Elswick, B., Guzelian, P. S. (1988) Regulation of gene expression in adult rat hepatocytes cultured on a basement membrane matrix. J. Cell. Physiol. 134,309-323[Medline]
  28. Nozawa, K., Kurumiya, Y., Yamamoto, A., Isobe, Y., Suzuki, M., Yoshida, S. (1999) Up-regulation of telomerase in primary cultured rat hepatocytes. J. Biochem. 126,361-367[Abstract/Free Full Text]
  29. Chawla, R. K., Watson, W. H., Eastin, C. E., Lee, E. Y., Schmidt, J., McClain, C. J. (1998) S-Adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury. Am. J. Physiol. 275,G125-G129[Abstract/Free Full Text]
  30. Engstrom, M. A., Benevenga, N. J. (1987) Rates of oxidation of the methionine and S-adenosylmethionine methyl carbons in isolated rat hepatocytes. J. Nutr. 117,1820-1826
  31. Bontemps, F., Van den Berghe, G. (1997) Metabolism of exogenous S-adenosylmethionine in isolated rat hepatocyte suspensions: methylation of plasma-membrane phospholipids without intracellular uptake. Biochem. J. 327,383-389
  32. Chiang, P. K. (1998) Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol. Ther. 77,115-134[Medline]
  33. Brada, Z., Bulba, S., Tershakovec, G. R. (1981) The dose-related metabolism of L-ethionine in acute experiments with rats. Res. Commun. Pathol. Pharmacol. 31,357-374
  34. Brada, Z., Hrsta, I., Bulba, S. (1988) Formation of S-adenosylethionine in liver of rats chronically fed with DL-ethionine. Cancer Res 48,4464-4468[Abstract/Free Full Text]
  35. Kimura, K., Jung, B. D., Kanehira, K., Irie, Y., Cañas, X., Saito, M. (1999) Induction of uncoupling protein (UCP) 2 in primary cultured hepatocytes. FEBS Lett 457,75-79[Medline]
  36. Carretero, M. V., Torres, L., Latasa, M. U., García-Trevijano, E. R., Prieto, J., Mato, J. M., Avila, M. A. (1998) Transformed but not normal hepatocytes express UCP2. FEBS Lett 439,55-58[Medline]
  37. Watson, W. H., Zhao, Y., Chawla, R. K. (1999) S-Adenosylmethionine attenuates the lipopolysaccharide-induced expression of the gene for tumour necrosis factor {alpha}. Biochem. J. 342,21-25
  38. Gil, B., Pajares, M. A., Mato, J. M., Alvarez, L. (1997) Glucocorticoid regulation of hepatic S-adenosylmethionine synthetase gene expression. Endocrionology 138,1251-1258[Abstract/Free Full Text]
  39. Hoffman, J. L. (1994) Bioactivation by S-adenosylation, S-methylation, or N-methylation. Thomas August, J. Anders, M. W. Murad, F. eds. Advances in Pharmacology ,449-477 Academic San Diego.
  40. Finkelstein, J. D., Martin, J. J. (1986) Methionine metabolism in mammals. J. Biol. Chem. 261,1582-1587[Abstract/Free Full Text]
  41. Matsumoto, C., Suma, Y., Tsukada, K. (1984) Changes in the activities of S-adenosylmethionine synthetase isozymes from rat liver with dietary methionine. J. Biochem. 95,287-290[Abstract/Free Full Text]
  42. Horikawa, S., Kobayasi, Y., Sugiyama, T., Terashima, H., Wada, K., Tsukada, K. (1993) Expression of non-hepatictype S-adenosylmethionine synthetase isozyme in rat hepatomas induced by 3'-mathyl-4-dimethylaminoazobenzene. FEBS Lett 334,69-71[Medline]
  43. Counts, J. L., Sarmiento, J. I., Harbison, M. L., Downing, J. C., McClain, R. M., Goodman, J. I. (1996) Cell proliferation and global methylation status changes in mouse liver after phenobarbital and/or choline-devoid, methionine-deficient diet administration. Carcinogenesis 17,1251-1257[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Wu and A. I. Cederbaum
Opposite action of S-adenosyl methionine and its metabolites on CYP2E1-mediated toxicity in pyrazole-induced rat hepatocytes and HepG2 E47 cells
Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G674 - G684.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
T. J. Jeon and K. W. Jeon
Gene switching in Amoeba proteus caused by endosymbiotic bacteria
J. Cell Sci., February 1, 2004; 117(4): 535 - 543.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. L. Martinez-Chantar, M. U. Latasa, M. Varela-Rey, S. C. Lu, E. R. Garcia-Trevijano, J. M. Mato, and M. A. Avila
L-Methionine Availability Regulates Expression of the Methionine Adenosyltransferase 2A Gene in Human Hepatocarcinoma Cells: ROLE OF S-ADENOSYLMETHIONINE
J. Biol. Chem., May 23, 2003; 278(22): 19885 - 19890.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. Santamaria, M. A. Avila, M. U. Latasa, A. Rubio, A. Martin-Duce, S. C. Lu, J. M. Mato, and F. J. Corrales
From the Cover: Functional proteomics of nonalcoholic steatohepatitis: Mitochondrial proteins as targets of S-adenosylmethionine
PNAS, March 18, 2003; 100(6): 3065 - 3070.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
J. M. MATO, F. J. CORRALES, S. C. LU, and M. A. AVILA
S-Adenosylmethionine: a control switch that regulates liver function
FASEB J, January 1, 2002; 16(1): 15 - 26.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. C. Lu, L. Alvarez, Z.-Z. Huang, L. Chen, W. An, F. J. Corrales, M. A. Avila, G. Kanel, and J. M. Mato
Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation
PNAS, April 18, 2001; (2001) 91016398.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. C. Lu, L. Alvarez, Z.-Z. Huang, L. Chen, W. An, F. J. Corrales, M. A. Avila, G. Kanel, and J. M. Mato
Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation
PNAS, May 8, 2001; 98(10): 5560 - 5565.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GARCÍA-TREVIJANO, E. R.
Right arrow Articles by AVILA, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GARCÍA-TREVIJANO, E. R.
Right arrow Articles by AVILA, M. A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS